Overview

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Status:
Recruiting

Trial end date:
2024-10-01

Target enrollment:
0

Participant gender:
All

Summary

This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Arog Pharmaceuticals, Inc.

Treatments:

Crenolanib
Cytarabine
Fludarabine
Idarubicin
Mitoxantrone

Criteria

Inclusion Criteria:

1. Confirmed diagnosis of AML according to World Health Organization (WHO) 2016
classification

2. Presence of FLT3-ITD and/or D835 mutation(s)

3. Subjects must be primary refractory or relapsed to 1st line intensive treatment for
AML or refractory or relapsed after second line of treatment for AML

4. Age ≥ 18 years and ≤ 75 years

5. Adequate hepatic function

6. Adequate renal functions

7. ECOG performance status ≤ 3

Exclusion Criteria:

1. Known clinically active central nervous system(CNS) leukemia

2. Severe liver disease

3. Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)

4. Prior anti-leukemia therapy within the 14 days prior to randomization. Prior use of
quizartinib or gilteritinib must be discontinued 21 days prior to randomization. Prior
use of hydroxyurea or other palliative treatment for leukocytosis is allowed.

5. Previous treatment with crenolanib or prior participation in clinical trial involving
crenolanib.